Ontology highlight
ABSTRACT:
SUBMITTER: Herting F
PROVIDER: S-EPMC4196549 | biostudies-literature | 2014 Sep
REPOSITORIES: biostudies-literature
Herting Frank F Friess Thomas T Bader Sabine S Muth Gunter G Hölzlwimmer Gabriele G Rieder Natascha N Umana Pablo P Klein Christian C
Leukemia & lymphoma 20140204 9
Obinutuzumab (GA101) is a novel glycoengineered type II CD20 antibody in development for non-Hodgkin lymphoma. We compared the anti-tumor activity of obinutuzumab and rituximab in preclinical studies using subcutaneous Z138 and WSU-DLCL2 xenograft mouse models. Obinutuzumab and rituximab were assessed alone and in combination with bendamustine, fludarabine, chlorambucil, doxorubicin and cyclophosphamide/vincristine. Owing to strong single-agent efficacy in these models, suboptimal doses of obinu ...[more]